Aromatase Inhibitors as Neoadjuvant Treatment in Elderly Patients with Locally Advanced Breast Cancer

Lucia Borgato, Antonella Brunello, Vittorina Zagonel, Tania Saibene and Silvia Michieletto

1. Oncologist, Medical Oncology Unit 1; 2. Director of Medical Oncology, Medical Oncology Unit 1; 3. Surgeon, Surgical Oncology Unit, Veneto Oncological Institute, IRCCS Padova, Italy.

Abstract
Pre-operative volume reduction of locally advanced breast cancers (LABC) is an issue of great importance when approaching elderly women, who often present with extensive disease along with a burden of co-morbidity which increases the risk of complications and mortality from treatment. A comprehensive geriatric evaluation is a necessary requirement before recommending any treatment in older patients. Endocrine treatment in the neoadjuvant setting allows disease control and downstaging of tumours and is fairly well tolerated. Tamoxifen has been the mainstay of endocrine therapy for patients unable to undergo surgery, but resistance eventually develops. Aromatase inhibitors (AIs) are superior to tamoxifen in this setting, with greater downstaging of the tumour and disease control. AIs are now the treatment of choice in elderly patients with oestrogen receptor-positive breast cancer who are being considered for neoadjuvant endocrine therapy. There are some data that definitive treatment with an AI for LABC in unfit patients may guarantee long-term control of disease.

Keywords
Neoadjuvant therapy, endocrine treatment, breast cancer, elderly patients, aromatase inhibitors

Disclosure: The authors have no conflicts of interest to declare.
Received: 12 January 2012 Accepted: 24 January 2012 Citation: European Oncology & Haematology, 2012,8(3):184–8. DOI: 10.17925/EOH.2012.08.3.184
Correspondence: Lucia Borgato, Medical Oncology 1, Veneto Oncological Institute, IRCCS, Via Gattamelata 64, 35128 Padova, Italy. E: lucia.borgato@gmail.com

Breast cancer is the most common type of cancer in the female population worldwide, with an estimated incidence of more than 1.3 million new cases and 458,000 deaths in 2008. Up to 30 % of breast cancers are reported to occur in women aged 70 years or over, however, due to the under-representation of elderly patients in cancer clinical trials, there are few data to help define the optimum treatment for these patients.

A retrospective study of trials submitted to the US Food and Drug Administration (FDA) for drug approval in the years 1995–2002 showed that the percentage of women aged 65 years and over enrolled in clinical trials of hormonal therapy for breast cancer closely matched the proportion of breast cancer patients of the same age in the US, but inclusion rates in chemotherapy trials are much lower. Although the elderly population is heterogeneous, 65 years does not seem to be the optimum threshold for defining an elderly patient, and most of the members of a National Comprehensive Cancer Network (NCCN) taskforce for breast cancer closely agree to set 70 years as a better cut-off point.

Locally advanced breast cancer (LABC) refers to patients diagnosed with large primary cancers and/or regional adenopathy. Its frequency has diminished greatly thanks to screening mammography and early detection. However, there are some populations, such as women in low-income countries or elderly women in industrialised countries, who continue to experience disproportionately high breast cancer mortality rates, as they are at an increased risk of having locally advanced disease at diagnosis. Data show that the frequency of LABC is indeed higher in elderly women, with 10 % of cases occurring in patients younger than 40 years but 30 % occurring in patients aged 70 years or over.

In oestrogen receptor-positive (OR+) tumours, hormonal therapy has been shown to have only minor toxicity and similar activity compared to chemotherapy, which makes it a very attractive option for elderly patients with locally advanced or extensive disease not amenable to breast-conserving surgery (BCS). Wyld et al. reported that 40 % of women with breast cancer aged 70 years or over were receiving pre-operative endocrine therapy in the UK in 2002.

Tamoxifen has been the mainstay of endocrine therapy for OR+ breast cancer for more than 30 years, beyond being the first drug to be used in the neoadjuvant setting for elderly or frail patients unable to undergo surgery or more toxic therapies.

It has been demonstrated that, for post-menopausal and elderly women with large breast tumours (more than 3 cm) and expression of oestrogen receptors, the administration of a third-generation aromatase inhibitor (AI) for some months results in a more consistent tumour volume reduction than is obtained with tamoxifen, allowing BCS to be performed in most cases.

There are three approved and currently available hormonal agents: the non-steroidal AIs letrozole and anastrozole and the steroidal AI exemestane. So far, all AIs have been demonstrated to be more effective than tamoxifen and, in a recently published randomised
 trial, they have been shown to be biologically equivalent, as neoadjuvant treatment, to tamoxifen. Although there are no statistical differences in overall survival (OS) between tamoxifen and AIs, progression-free survival (PFS) is better in patients who have been treated with an AI.

Several trials have assessed the efficacy and safety of neoadjuvant endocrine therapy using AIs in post-menopausal patients with breast cancer. Trials considering the three available drugs are discussed below under the relevant drug. Activity data for the AIs used in these trials are presented in Table 1.

Overall, side effects induced by currently prescribed AIs are similar for all AIs combined, displaying an ‘AI class effect’ pattern of adverse events. These adverse events comprise hot flushes, nausea, diarrhoea and vomiting, arthralgias/myalgias and that often give rise to a polymyalgia-like syndrome, blood lipid disorders (with hypercholesterolaemia and/or hypertriglyceridaemia) and loss of bone mass (with a higher risk of bone fractures and worsening of osteoporosis). When compared with other endocrine treatment, however, there is, with AIs, a decreased risk of vaginal bleeding and of thromboembolic events.

**Letrozole**

Letrozole (4,4’-[1H-1,2,4-triazol-1-ylmethyl]-1,3-phenylene)bis(benzonitrile) is an orally administered non-steroidal competitive aromatase enzyme inhibitor that has been shown to be more effective than tamoxifen in terms of response rate and time to progression as first-line treatment for post-menopausal women with locally advanced and metastatic breast cancer. Research about the efficacy of letrozole in the pre-operative setting is increasing.

The large randomised controlled trial P024 compared letrozole 2.5 mg versus tamoxifen 20 mg for four months as neoadjuvant treatment for post-menopausal patients with oestrogen- and/or progesterone-positive (OR/PR+) untreated primary breast cancer. Three hundred and thirty patients were enrolled and a significantly higher overall response rate, evaluated by clinical palpation, was reported in the letrozole arm (55 % versus 36 %, p<0.001), with fair tolerance in both arms. Treatment response was also assessed by ultrasound and mammograms, which confirmed the better results with letrozole. Notably, there was a lower rate of BCS in the tamoxifen group than in the letrozole group (35 % versus 45 %, p=0.002). The median age of patients treated with letrozole was 68 years and both study arms included a high proportion of patients aged 70 years or over (46 % in the letrozole arm and 42 % in the tamoxifen arm). A subanalysis to investigate the correlation between age (<70 years, ≥70 years) and objective response was conducted but did not show any significant results.

Dixon et al. investigated the possibility of a different antitumour activity of letrozole when used at a daily dose of 2.5 mg, compared with a daily dose of 10 mg, as primary neoadjuvant treatment in post-menopausal patients with OR/PR+ LABC. In this single-centre study involving 24 patients treated for three months, no significant differences in objective response (clinically assessed) between the two doses were observed. The safety profile was acceptable both in the group of patients treated with letrozole 2.5 mg (in which the mean age was 77.6 years and the age range 61–87) and in the group treated with the 10 mg dose (mean age 71.6, range 52–84).

On the basis of some evidence that human epidermal growth factor receptor-2 (HER2) overexpression may confer resistance to tamoxifen in OR/PR+ breast tumours, and overexpression of HER1 as well as, a biomarker subanalysis of the P024 study was carried out to analyse the relationship between the expression of HER1 and HER2 and the response to letrozole. A significantly higher response rate was observed in patients with OR/PR+, HER2+ and HER1+ breast tumours treated with letrozole compared with patients treated with tamoxifen (88 % versus 21 %, p=0.0004). Letrozole was equally effective in HER2+ and HER2- tumours. These data suggest that pre-operative letrozole could be an effective alternative to tamoxifen in OR/PR+, HER2+ and HER1+ breast tumours.

**Anastrozole**

Anastrozole (2,2’-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis (2-methylpropanenitrile) is an orally administered competitive non-steroidal aromatase enzyme inhibitor.

In a Phase II clinical trial, Milla-Santos et al. reported a high antitumour activity of pre-operative anastrozole in post-menopausal patients with hormone-dependent breast tumours. One hundred and twelve patients with a median age of 64.7 years (range 56–73) received anastrozole 1 mg for three months; an objective response rate (ORR) of 83 % and a low incidence of side effects were reported.

Consistent with previous findings, Dixon et al. observed that pre-operative anastrozole was able to induce a median reduction in tumour volume (detected on ultrasound) of ≥75 % (95 % confidence interval 51–79) in a majority of 24 women treated with anastrozole given at a daily dose of 1 mg or 10 mg for 12 weeks.

Moreover, two randomised controlled trials evaluated the neoadjuvant use of anastrozole. In the Pre-operative Arimidex® compared to tamoxifen (PROACT) study, anastrozole was compared with tamoxifen as a pre-operative treatment for post-menopausal women with OR/PR+ and/or progesterone-positive (OR/PR+) breast cancer. One hundred and twelve patients with OR+ and HER2+ tumours (the ORR for patients with HER2+ tumours treated with anastrozole compared with tamoxifen was 58 % for anastrozole and 21 % for tamoxifen [p=0.18]). The ORR, assessed using both ultrasound and calliper, was slightly higher with anastrozole compared with tamoxifen, although not statistically different (36.2 % versus 26.5 %, p=0.07 and 49.7 % versus 39.7 %, p=0.08, respectively). On the other hand, anastrozole significantly improved surgery rates in patients deemed amenable to surgery at baseline (43.0 % versus 30.8 %, p=0.04).

Similar results were obtained in the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) trial, in which 330 women (median age 73 years) were randomly assigned to be treated with anastrozole or tamoxifen or a combination of the two for 12 weeks before surgery. A significant difference in clinical ORR and in BCS rate was not reached between the three groups. However, a trend in favour of anastrozole compared with tamoxifen was reported among patients with OR+ and HER2+ tumours (the ORR for patients with HER2+ cancer was 58 % for anastrozole versus 22 % for tamoxifen [p=0.18]).

Results do reinforce the hypothesis that AIs may be more effective than tamoxifen in the treatment of OR+ early breast cancer that also overexpresses HER2, and the lack of significance could be due to the small patient numbers and underpowered design of the study.
Breast Cancer

Table 1: Activity/Efficacy of Aromatase Inhibitors in Neoadjuvant Setting

<table>
<thead>
<tr>
<th>Study</th>
<th>Drug</th>
<th>n</th>
<th>Phase</th>
<th>Median Age (Years)</th>
<th>Objective Response Rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mustacchi et al., 2009&lt;sup&gt;39&lt;/sup&gt;</td>
<td>Exemestane</td>
<td>117</td>
<td>II</td>
<td>80</td>
<td>69.6</td>
</tr>
<tr>
<td>Mileritsch et al., 2008&lt;sup&gt;40&lt;/sup&gt;</td>
<td>Exemestane</td>
<td>80</td>
<td>II</td>
<td>71</td>
<td>74*</td>
</tr>
<tr>
<td>Takei et al., 2008&lt;sup&gt;41&lt;/sup&gt;</td>
<td>Exemestane</td>
<td>44</td>
<td>II</td>
<td>60</td>
<td>66*</td>
</tr>
<tr>
<td>Toi et al., 2011&lt;sup&gt;42&lt;/sup&gt;</td>
<td>Exemestane</td>
<td>116</td>
<td>II</td>
<td>64</td>
<td>51 (after 24 weeks)</td>
</tr>
<tr>
<td>Krainick et al., 2003&lt;sup&gt;43&lt;/sup&gt;</td>
<td>Exemestane</td>
<td>27</td>
<td>II</td>
<td>71</td>
<td>40</td>
</tr>
<tr>
<td>Tubiana-Hulin et al., 2007&lt;sup&gt;44&lt;/sup&gt;</td>
<td>Exemestane</td>
<td>45</td>
<td>II</td>
<td>67.6</td>
<td>73.3*</td>
</tr>
<tr>
<td>Semigliazov et al., 2005&lt;sup&gt;45&lt;/sup&gt;</td>
<td>Exemestane versus tamoxifen</td>
<td>151</td>
<td>II</td>
<td>Not reported</td>
<td>76.3 versus 40 (p&lt;0.05)</td>
</tr>
<tr>
<td>Barnadas et al., 2009&lt;sup&gt;46&lt;/sup&gt;</td>
<td>Exemestane</td>
<td>55</td>
<td>II</td>
<td>76</td>
<td>61*</td>
</tr>
<tr>
<td>Krainick-Strobel et al., 2008&lt;sup&gt;47&lt;/sup&gt;</td>
<td>Letrozole</td>
<td>32</td>
<td>ib/III</td>
<td>Not reported</td>
<td>71.9</td>
</tr>
<tr>
<td>Eiermann et al., 2001&lt;sup&gt;48&lt;/sup&gt;</td>
<td>Letrozole versus tamoxifen</td>
<td>154</td>
<td>III</td>
<td>68 versus 67</td>
<td>55 versus 36 (p&lt;0.001)</td>
</tr>
<tr>
<td>Dixon et al., 2001&lt;sup&gt;49&lt;/sup&gt;</td>
<td>Letrozole 2.5 mg versus letrozole 10 mg</td>
<td>12</td>
<td>II/III</td>
<td>77.6 versus 71.6</td>
<td>Not reported</td>
</tr>
<tr>
<td>Milla-Santos et al., 2004&lt;sup&gt;50&lt;/sup&gt;</td>
<td>Anastrozole</td>
<td>112</td>
<td>ii</td>
<td>64.7</td>
<td>83</td>
</tr>
<tr>
<td>Dixon et al., 2000&lt;sup&gt;51&lt;/sup&gt;</td>
<td>Anastrozole 1 mg versus anastrozole 10 mg</td>
<td>13</td>
<td>versus 13</td>
<td>Not reported</td>
<td>91</td>
</tr>
<tr>
<td>Cataliotti et al., 2006&lt;sup&gt;52&lt;/sup&gt;</td>
<td>Anastrozole versus tamoxifen</td>
<td>228</td>
<td>III</td>
<td>67.3 versus 66.7</td>
<td>50 versus 46.2 (p&lt;0.37)</td>
</tr>
<tr>
<td>Smith et al., 2005&lt;sup&gt;53&lt;/sup&gt;</td>
<td>Anastrozole versus tamoxifen versus combination</td>
<td>113</td>
<td>versus 108</td>
<td>73.2 versus 71.5</td>
<td>37 versus 36 versus 39*</td>
</tr>
<tr>
<td>Ellis et al., 2011&lt;sup&gt;54&lt;/sup&gt;</td>
<td>Exemestane versus letrozole versus anastrozole</td>
<td>124</td>
<td>versus 123</td>
<td>69 versus 65</td>
<td>62.9 versus 74.8 versus 69.1</td>
</tr>
<tr>
<td>Brunello et al., 2011&lt;sup&gt;55&lt;/sup&gt;</td>
<td>Anastrozole, letrozole, exemestane</td>
<td>66</td>
<td>Retrospective</td>
<td>82</td>
<td>86.4*</td>
</tr>
<tr>
<td>Dixon et al., 2010&lt;sup&gt;56&lt;/sup&gt;</td>
<td>Letrozole</td>
<td>79</td>
<td>Retrospective</td>
<td>81</td>
<td>65 and 43*</td>
</tr>
</tbody>
</table>

* Caliper assessment; ** Endocrine therapy-only patients; † frail patients; ‡ reported progression-free survival at 2 and 5 years.

Exemestane

Exemestane (6-methylidenedioestra-1,4-diene-3,17-dione) is an irreversible steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It is administered orally. Primary use of exemestane has been evaluated in several studies, mainly Phase II trials. Overall response rates are consistently high, with more than two-thirds of patients worldwide experiencing partial responses.

In a small Phase II trial with in vivo correlative studies, it was demonstrated that neoadjuvant exemestane causes shrinkage of tumours in more than 80 % of patients, along with markedly reducing cellular proliferation and progesterone receptor expression.

In the German neoadjuvant Aromasin® initiative (GENARI) trial, patients with a median age of 71 years received exemestane for four months prior to surgery. Overall response rates were about 40 %, and more than half the patients were eventually treated with BCS.

In an Italian study by Mustacchi et al. specifically looked at elderly patients. The median age of the 117 patients enrolled was 80 years. The overall response rate, assessed by means of either clinical and radiological or clinical-only evaluation, was 69.6 %. Surgery was then performed in two-thirds of patients.

Comprehensive Geriatric Assessment

There is general agreement that evaluation of breast cancer-related mortality risk and of other patient-related factors, such as functional status, co-morbidities, cognition and psychosocial issues, is to be assessed to individualise treatment for older patients.

In a recently published Spanish Phase II trial, 55 patients with OR+ breast cancer ineligible for BCS at baseline (mean age 76 years) were recruited to receive oral exemestane 25 mg daily for six months. Tumour response was evaluated by clinical examination, mammography and breast ultrasound every two months. Overall clinical response to treatment was observed in 61 % of patients. The median time to surgery from the beginning of treatment was seven months. BCS was eventually performed in more than half the patients, 34.5 % underwent to mastectomy and 21 % did not undergo surgery, either because they chose not or because the physician did not consider them to be suitable. No severe adverse events were detected.

An Italian study by Mustacchi et al. specifically looked at elderly patients. The median age of the 117 patients enrolled was 80 years. The overall response rate, assessed by means of either clinical and radiological or clinical-only evaluation, was 69.6 %. Surgery was then performed in two-thirds of patients.
Aromatase Inhibitors as Neoadjuvant Treatment in Elderly Patients with LABC

According to the CGA, patients may be classified into three main groups:

- ‘fit’ patients, which includes subjects presenting no limitation in activities of daily living (ADLs) and with no major co-morbidity, who present rough mortality rates at two years of 8–12 %;
- ‘frail’ patients, who are patients older than 85 years or those presenting with severe co-morbidity or functional dependence in ADLs, or with geriatric syndromes (dementia, delirium, severe osteoporosis, depression, failure to thrive, inability to gain weight, falls, incontinence), with mortality rates higher than 40 %; and
- in between are the majority of elderly patients defined as ‘vulnerable’, who are dependent in some instrumental activities of daily living (IADLs), but not in ADLs, or who present manageable co-morbidity with appropriate treatment; their mortality rates are approximately 16–25 % at two years.53

Generally, elderly patients who are deemed frail at the CGA have a rough two-year mortality of 40 % independently of the diagnosis of cancer; therefore recommendations have been made to deliver only best supportive care.11

Several studies on CGA show that for patients with breast cancer functional status is indeed a predictive factor for survival, for mortality and for toxicity from treatments.54,55

Severe osteoporosis or severe dyslipidaemia may in some cases contraindicate treatment with AIs. CGA, and in particular careful detection of co-morbidity, could be a useful tool in such cases for selection of patients that could derive benefit from endocrine treatment with tamoxifen instead of AIs.

Given these considerations, the approach to older adults with breast cancer must include a multidimensional comprehensive geriatric evaluation in order to unveil potential weakness that may result in severe toxicity or complications from treatment and to maximise benefits.56

On this view, endocrine therapy may be a good option for those patients having large OR/PR+ breast tumours in which immediate surgery may lead to functional impairment or may be contraindicated, and chemotherapy may result in unacceptable toxicities.

Treatment duration – Primary and Definitive Treatment

A critical question about neoadjuvant treatment with an AI is for how long to treat in the pre-operative setting. To date, there is no defined median treatment duration.

Usually, neoadjuvant endocrine treatment is prolonged for 3–4 months before surgery.57,58,59 According to the study by Kranick-Strobel et al., a minimum of four months of therapy is necessary, yet a longer duration of treatment may lead to better results. In this study, which specifically addressed the question of pre-operative treatment duration, 32 patients were treated with letrozole 2.5 mg orally daily for 4–8 months and clinical and radiological tumour response was evaluated. Unfortunately, the trial was stopped prematurely due to slow recruitment, but available data support the consideration that prolonged treatment for up to eight months rather than an early interruption after four months can result in further tumour volume reduction in some patients.60

To date, conclusive data on the optimal duration of pre-operative endocrine treatments for OR/PR+ breast cancer in post-menopausal women are still not available.

Recommendation from the panel of experts at the St Gallen consensus conference held in 2011 are for the continuation of treatment until maximum response is obtained, or for a minimum of 4–8 months.17

In some cases, given the high response rate reached with AIs, some elderly patients (≥70 years old) may be spared surgery. A review of seven randomised trials showed no difference in OS for patients undergoing primary endocrine therapy with tamoxifen when compared with surgery, with or without tamoxifen.61 However, the patients who underwent surgery experienced a lower rate of relapse; therefore a recommendation can be made that primary endocrine therapy with tamoxifen should be suggested if patients are unfit for surgery. However, only scarce data are available for primary, definitive treatment with third-generation AIs.

In most of the studies of neoadjuvant endocrine treatment, the majority of patients were then treated with surgery.62,63 However, there are some data from retrospective studies specifically addressed to elderly patients in which response rates with the use of AIs as neoadjuvant treatment are fairly high and survival rates are quite encouraging, despite the fact that surgery was performed only in a minority of cases.64,65

In a small Scottish study,66 most patients were deemed frail and therefore not candidates for surgery. However, PFS rates were 65 % and 43 %, respectively, at 2 and 5 years from beginning of treatment with letrozole, with OS at 2 years of 76 %, at 5 years of 32 %.

In an Italian study by Brunello et al.,67 a large proportion of patients (57.6 %) were deemed frail following the CGA; at two and five years, PFS rates were 95 % and 85 % and OS rates were 95 % and 64 %, respectively. Less than half received further antineoplastic treatments and only with endocrine drugs. In this study, surgery was eventually performed in 10 % of patients only.

A possible suggestion is therefore that, depending on the results of CGA, surgery may be omitted without significantly compromising PFS and OS in frail or unfit patients.

Conclusions

Since the optimal endocrine treatment schedule remains to be determined, prospective observational and randomised studies are needed to better assess not only the clinical benefit of neoadjuvant treatment with AIs but also resistance which may develop in case it is administered as ‘definitive’ treatment. Furthermore, possible risks correlated with long-term use such as osteoporosis, which could affect morbidity and mortality beyond oncological disease, need to be investigated.68

In the effort to optimise treatment for elderly patients, we should promote the conduct of such studies specifically addressed to the elderly using standardised tools of assessment in order to weigh the benefits achieved with treatment, such as tumour response, against quality of life and preservation of functional autonomy, which remain the most relevant outcome measure in unfit elderly patient.


43. Semiglavsky VF, Semiglavsky VV, Ivanov VI, et al., Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (27N-2, 37N-3, 14N), J Clin Oncol 2005;23(Suppl. 16):Abstract 530.


47. van den Bergh, Rentjes J, Keys J, et al., Outcome of frail elderly patients treated with letrozole alone, Cancer Res 2010;70:2244–51, Abstract P1.06.


